Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

 
News
 
 
Language
 
Thursday, January 21. 2016
 
Basel, Switzerland, January 21, 2016 - GSK (GlaxoSmithKline) informed Basilea today that it has elected to discontinue its U.S. alitretinoin program. Global rights to Toctino (alitretinoin) were transferred to Stiefel, a GSK company, in July 2012. Basilea has the option to re-acquire the U.S. alitretinoin rights. GSK continues to commercialize Toctino in its current markets.
 
more...
 
Tuesday, December 29. 2015
 
Basel, Switzerland, December 29, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that Heidi Mc Daid, Head of Global Human Resources and member of the management committee, will retire effective December 31, 2016.
 
more...
 
Monday, December 28. 2015
 

This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan and does not constitute an offer of securities for sale in such countries

  • Ceftobiprole U.S. clinical phase 3 program discussed with FDA
  • Interim data from phase 1/2a study with tumor checkpoint controller BAL101553 show signals of clinical benefit
 
more...
 
Friday, December 18. 2015
 
This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan and does not constitute an offer of securities for sale in such countries
 
more...
 
Info
 
 
 

IDSA
Infectious Diseases
Society of America